

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (date of earliest event reported): May 16, 2016**

---

**OPEXA THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

**Texas**  
(State or other jurisdiction of  
incorporation)

**001-33004**  
(Commission File Number)

**76-0333165**  
(IRS Employer Identification No.)

**2635 Technology Forest Blvd., The Woodlands, Texas**  
(Address of principal executive offices)

**77381**  
(Zip Code)

Registrant's telephone number, including area code: **(281) 272-9331**

**N/A**

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.07 Submission of Matters to a Vote of Security Holders**

The Annual Meeting of Shareholders for Opexa Therapeutics, Inc. was held on May 16, 2016 (the “Annual Meeting”). Four proposals were submitted to shareholders as described in the 2016 Proxy Statement and were approved by shareholders at the Annual Meeting. The proposals and the results of the shareholder votes are as follows.

## 1. Proposal to elect six directors for one-year terms:

	<u>For</u>	<u>Withheld</u>	<u>Broker Non-Votes</u>
Timothy C. Barabe	1,350,520	149,738	3,439,982
Hans-Peter Hartung	1,058,783	441,475	3,439,982
Gail J. Maderis	1,349,515	150,743	3,439,982
Michael S. Richman	1,349,704	150,554	3,439,982
Scott B. Seaman	1,350,668	149,590	3,439,982
Neil K. Warma	1,339,552	160,706	3,439,982

## 2. Proposal to approve the Amended and Restated 2010 Stock Incentive Plan:

<u>For</u>	<u>Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
1,237,868	241,814	20,576	3,439,982

## 3. Proposal to hold an advisory “say-on-pay” vote on the compensation of the Named Executive Officers:

<u>For</u>	<u>Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
1,239,707	229,349	31,202	3,439,982

## 4. Proposal to ratify the appointment of MaloneBailey, LLP as independent auditors for the fiscal year ending December 31, 2016:

<u>For</u>	<u>Against</u>	<u>Abstain</u>	<u>Broker Non-Votes</u>
4,865,393	59,246	15,601	0

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: May 18, 2016

OPEXA THERAPEUTICS, INC.

By: /s/ Neil K. Warma

\_\_\_\_\_  
Neil K. Warma  
President, Chief Executive Officer and  
Acting Chief Financial Officer